PTPRC and neoplasm: After treating tumor-bearing liver CD45+ cells with CEBPδ-siRNA, we pre-injected these cells intravenously into tumor-bearing mice, followed by injection of fluorescent-labeled tumor cells (Fig. 4a, experimental model).